In a report released today, Anthony Petrone from Jefferies maintained a Buy rating on Haemonetics Corp (NYSE: HAE), with a price target of $110. The company’s shares closed yesterday at $91.75, close to its 52-week high of $96.32.
Petrone has an average return of 23.9% when recommending Haemonetics Corp.
According to TipRanks.com, Petrone is ranked #755 out of 4830 analysts.
Haemonetics Corp has an analyst consensus of Strong Buy, with a price target consensus of $100.
Based on Haemonetics Corp’s latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $11.88 million. In comparison, last year the company had a GAAP net loss of $51.14 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Haemonetics Corp. is a healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following geographical segments: Japan, EMEA (Europe, the Middle East, and Africa), North America Plasma, and All Other.